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Volume 194The prevalence of atrial fibrillation (AF) in the United
States has been projected to increase 2.5-fold by 2050 to
5.6 million individuals and was estimated at 33.5 million
worldwide in 2010.1-3 International population-based
studies have identified an 18% rise in disability-adjusted
life-years attributable to AF globally.2 This growth has
been attributed to several factors, including aging
populations, more chronic cardiovascular disease, and
increasing prevalence of AF risk factors, such as obesity.4
However, although prior studies have provided evidence
of regional differences in incidence and demographics,
no in-depth data on this worldwide epidemic have been
reported.
In this setting, several disease-specific, prospective
observational registry programs were created to better
understand AF populations, their demography, treat-
ments, and clinical outcomes. Internationally, the Global
Anticoagulant Registry in the FIELD–Atrial Fibrillation
(GARFIELD-AF) registry enrolled patients from around
the globe and culminated in a population of more than
57,000 patients recruited over the course of 5 phases in
35 countries. The largest in the United States, the
Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation (ORBIT-AF) program, includes 2 phases
of enrollment totaling nearly 25,000 patients. Collabora-
tion between the programs will yield powerful insights
regarding AF population characteristics globally, treat-
ments, and outcomes among regions, and allow for
investigation of phenomena too rare to explore in
individual cohorts. In this analysis, we compared the
baseline populations from the GARFIELD-AF and
ORBIT-AF programs, including comparisons of baseline
stroke and bleeding risk profiles, as well as variations in
the prescribing practice for stroke prevention by region
and by stroke-risk profile.Methods
These analyses include data from all 5 enrollment
cohorts of the GARFIELD-AF registry and both phases of
the ORBIT-AF program. Separate data from each program
are presented side-by-side for comparison.
GARFIELD-AF
GARFIELD-AF is an international prospective noninter-
ventional registry of patients who were enrolled within
6 weeks of diagnosis of nonvalvular AF. Patients were
included if they had at least 1 additional risk factor for
stroke as defined by the patient's physician. This could
include a CHA2DS2-VASc risk factor or an alternative
characteristic that the physician felt increased the patient's
risk of stroke (and was not collected). Neither treatment
with stroke prevention therapy nor minimum CHADS2 or
CHA2DS2-VASc score was required for inclusion.
To reflect real-world care delivery, site makeup in
GARFIELD-AF varied according to geography. For eachcountry, delivery care patterns were assessed, and
randomly selected generalist and specialty providers
were invited to participate so that the balance of sites,
by country, reflected local AF care. These could include
primary care physicians, internal medicine, geriatricians,
cardiologists, and/or neurologists.
Patient demographic, medical history, AF history,
electrocardiographic and laboratory data, imaging, and
medical and interventional treatments were prospective-
ly recorded in a Web-based case report form. Patients
were enrolled chronologically in 5 consecutive cohorts
beginning in December 2010 with the completion of
enrollment in July 2016. Follow-up will conclude in 2018,
with a minimum of 2-year follow-up (for cohort 5) and a
maximum of 7-year follow-up (for patients enrolled in
cohort 1).
As a sensitivity analysis, the design of the GARFIELD-AF
program included a retrospective cohort of patients with
known AF as part of cohort 1. As in prior analyses from
GARFIELD-AF, data from that retrospective cohort are
not included in this analysis. The complete design and
methods of the GARFIELD-AF registry have been
described in detail previously. 5 All patients in
GARFIELD-AF signed written informed consent, and
GARFIELD-AF received regulatory approval pursuant to
local policies.
ORBIT-AF
The ORBIT-AF program included 2 separate, obser-
vational US registries: ORBIT-AF I and ORBIT-AF II.
The ORBIT-AF I cohort was enrolled from 2010 to
2011 and included adult patients with electrocardio-
graphically proven AF not due to a reversible cause.
Enrollment in ORBIT-II occurred between 2013 and
2016 and had additional inclusion criteria: patients
either had to have a recent diagnosis of AF (b6
months) and/or they had to have recently transi-
tioned to a non–vitamin K oral anticoagulant (NOAC;
b3 months). Because of these differences in entry
criteria, the 2 ORBIT-AF cohorts are presented separately
here.
Patients were enrolled in each phase of ORBIT-AF from
a nationally representative sample of sites providing care
for patients with AF in the United States, and there was
significant overlap between sites participating in
ORBIT-AF I and ORBIT-AF II. They included primary
care physicians, cardiologists, electrophysiologists, and
neurologists. Similar clinical data were collected in each
phase of ORBIT-AF: baseline demographics, medical
history, vital signs, laboratory data, imaging and electro-
cardiographic data, AF symptoms and history, and
medical and interventional therapies received. These
data elements were entered into aWeb-based case report
form.
Complete details of the ORBIT-AF I and ORBIT-AF II
registry designs have been previously described.6,7 Each
Table I. Selected comparisons between the GARFIELD-AF and ORBIT-AF registry programs
GARFIELD-AF5 ORBIT-AF I6 ORBIT-AF II7
Enrollment period 2010-2016 2010-2011 2013-2016
Geography Worldwide (35 countries,primarily non-US) US only US only
Size (approx.) 51,270 10,000 13,400
AF criteria New onset b6 wk New onset or prevalent(any type)
New onset (≤6 m) or new
NOAC (≤3 m)
AF diagnosis Nonvalvular AF diagnosed according to standard local procedures AF, valvular or nonvalvular AF, valvular or nonvalvular
Stroke risk inclusion criteria 1 additional risk factor required (physician-defined) No requirement No requirement
Abbreviations: AF, atrial fibrillation; GARFIELD-AF, Global Anticoagulant Registry in the FIELD – Atrial Fibrillation; ORBIT-AF, Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation; NOAC, non-Vitamin K antagonist oral anticoagulant.
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University institutional review board as well as by
governing oversight groups pursuant to local regulations.
All patients provided written informed consent.
Registry methods compared
Notable distinguishing characteristics of each registry
design are shown in Table I. Importantly, GARFIELD-AF
included only patients with a diagnosis of AF within 6
weeks of enrollment, whereas ORBIT-AF I enrolled
patients irrespective of time since diagnosis, and
ORBIT-AF II only required a recent diagnosis (b6
months) for patients not recently switched to a NOAC.
The additional distinguishing characteristic of the
GARFIELD-AF registry was a requirement for at least 1
investigator-defined risk factor for stroke in addition to
AF—this was not required in either ORBIT-AF phase.
Lastly, GARFIELD-AF excluded patients with valvular AF
(as defined by local practice), whereas both ORBIT-AF
registries allowed valvular and nonvalvular AF.
Patient involvement
Patients were not involved in the design, recruitment,
or conduct of this analysis; however, outcomes measured
by these registries are informed by previously described
patient priorities. These include clinically relevant events
such as stroke and major bleeding. Study burden to
patients was minimized, as no additional follow-up visits
or testing was performed beyond those carried out as part
of routine clinical care.
Statistical methods
Summary statistics of the baseline populations of
GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II are described
using percentages or means (95% CIs), as appropriate.
These included baseline demographics, vital signs,
medical history, laboratory and imaging data, as well as
baseline medical therapies. Comparison statistical tests
are not calculated because the large sample sizes are
likely to yield statistically significant differences that may
or may not be clinically relevant.For analyses of patients with new-onset AF, all cohorts
were limited to patients diagnosed with AF within 6
weeks of enrollment. ORBIT-AF I included a small
number of these patients, and so this cohort was
excluded from this analysis of patients stratified by
CHA2DS2-VASc.
Analyses of the data from GARFIELD-AF were per-
formed by the Thrombosis Research Institute using
SAS software (version 9.4; SAS Institute, Cary, NC).
Analyses of the deidentified data from ORBIT-AF were
performed by the Duke Clinical Research Institute
using SAS software (version 9.3; SAS Institute, Cary,
NC). The Thrombosis Research Institute and the
GARFIELD-AF registry are supported by an unrestrict-
ed research grant from Bayer AG, Berlin, Germany.
The ORBIT-AF registry is sponsored by Janssen
Scientific Affairs, LLC, Raritan, NJ. The authors are
solely responsible for the design and conduct of this
study, all study analyses, the drafting and editing of the
paper, and its final contents.Results
Patient demographics and clinical characteristics
The prospective population of GARFIELD-AF included
51,270 patients from 1,314 sites in 35 countries
(including the United States). The ORBIT-AF I population
included 10,132 patients from 174 US sites, and ORBIT-AF
II included 11,602 patients from 242 US sites. Baseline
characteristics of these 3 groups are shown in Table II.
Patient age (mean 70-74 years) and female sex (about
42%-44%) were roughly balanced across the studies.
However, there was variability in ethnic makeup across
studies (63% of patients were white in GARFIELD-AF vs
85%-89% in ORBIT-AF I and II). Coronary artery disease
was less common in the international GARFIELD-AF
cohort (19% vs 36% and 27% for ORBIT-AF I and II,
respectively). However, more than three-quarters of all
patients had hypertension, and approximately one-fifth
had diabetes in all studies. Patient characteristics,
stratified by enrolling provider type (generalist vs
Table II. Demographics, past medical history, and risk scores among all patients in GARFIELD-AF, ORBIT-AF I, and ORBITAF II
GARFIELD-AF (n = 51,270) ORBIT-AF I (n = 10,132) ORBIT-AF II (n = 11,602)
Age, y 69.7 (69.6, 69.8) 73.5 (73.2, 73.7) 70.3 (70.1, 70.5)
Female 22,669 (44.2) 4293 (42.4) 4822 (41.6)
Race
White 31,595 (63.2) 9041 (89.2) 9917 (85.5)
Black/African American 232 (0.5) 506 (5.0) 571 (4.9)
Hispanic 3315 (6.6) 425 (4.2) 641 (5.5)
Asian 61 (0.6) 218 (1.9)
Non-Chinese 11,379 (22.7)
Chinese 2684 (5.4)
Hypertension 39,025 (76.3) 8411 (83.0) 9229 (79.6)
Diabetes 11,317 (22.1) 2982 (29.4) 3034 (26.2)
Prior stroke/TIA 5858 (11.4) 1528 (15.1) 1249 (10.8)
CAD 6633 (19.4) 3645 (36.0) 3084 (26.6)
Prior CABG 1599 (3.2) 1487 (14.7) 1024 (8.8)
PAD 2806 (5.5) 1355 (13.4) 924 (8.0)
CHF 10,260 (20) 3297 (32.5) 2437 (21.0)
NYHA I 1792 (19.2) 1045 (31.9) 789 (33.2)
NYHA II 4536 (48.5) 1504 (45.9) 1148 (48.4)
NYHA III 2605 (27.8) 663 (20.2) 410 (17.3)
NYHA IV 423 (4.5) 64 (2.0) 26 (1.1)
BMI, kg/m2 27.8 (27.7, 27.8) 30.5 (30.4, 30.7) 31.2 (31.0, 31.3)
Heart rate, beat/min 90.4 (90.2, 90.7) 71.9 (71.7, 72.2) 75.1 (74.8, 75.4)
SBP, mm Hg 133.5 (133.3, 133.7) 126.5 (126.2, 126.8) 127.8 (127.5, 128.2)
DBP, mm Hg 79.7 (79.6, 79.8) 73.0 (72.8, 73.3) 74.7 (74.5, 74.9)
Time from AF diagnosis
b6 wk 51,270 (100) 370 (3.7) 4574 (39.4)
Mean time from diagnosis to enrollment (wk) 2.0 (1.9, 2.2) 303.4(296.8, 310.1) 84.5 (80.9, 88.1)
CHA2DS2-VASc scores
Low: 0 1404 (2.8) 225 (2.2) 476 (4.1)
Moderate: 1 6095 (12.2) 705 (7.0) 1269 (10.9)
High: ≥2 42,453 (85.0) 9202 (90.8) 9856 (85.0)
HAS-BLED scores
Low: 0 5386 (14.6) 613 (6.6) 1670 (14.4)
Medium: 1-2 27,419 (74.2) 6443 (69.1) 8174 (70.6)
High: ≥3 4171 (11.3) 2271 (24.3) 1731 (15.0)
Specialty
Primary/general practice 7339 (14.3)
1978 (19.5) 925 (8.0)Internal medicine 9211 (18.0)
Geriatrics 198 (0.4)
Cardiology 33,650 (65.6) 6610 (65.2) 7999 (69.0)
Electrophysiology 1544 (15.2) 2591 (22.3)
Neurology 870 (1.7) 86 (0.7)
Values are presented as n (%) or mean (95% CI), unless noted otherwise.
TIA, Transient ischemic attack; CAD, coronary artery disease; CABG, coronary artery bypass grafting; PAD, peripheral arterial disease; CHF, congestive heart failure; NYHA, New
York Heart Association; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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(Table S1).
Distributions of stroke (CHA2DS2-VASc) and bleeding
(HAS-BLED) risk scores for each of the overall populations
are shown in Figure 1. These distributions were
minimally skewed toward lower stroke risk for
GARFIELD-AF compared with the ORBIT-AF cohorts.
Overall, N85% of patients in both registry programs
had high stroke risk (CHA2DS2-VASc ≥2), whereas
high bleeding risk (HAS-BLED score ≥3) was
present in 11% (GARFIELD-AF) to 24% (ORBIT-AF I)
of patients.Treatment of patients with new-onset AF
Among patients with AF diagnosed within 6 weeks,
stroke prevention therapies are shown in Figure 2. Use
of NOACs, with and without antiplatelet therapies,
increased over the study periods of both the
GARFIELD-AF (3% NOAC in 2010 to 43% in 2016) and
ORBIT-AF programs (2% NOAC in ORBIT-AF I in 2010
to 71% NOAC in ORBIT-AF II in 2016). Use of
antiplatelet therapy alone for stroke prevention de-
creased over time in both programs (from 36% to 17%
in GARFIELD-AF and from 18% to 8% in the ORBIT-AF
program).
Figure 1
Distribution of CHA2DS2-VASc stroke risk (A) and HAS-BLED (B) bleeding risk in the GARFIELD-AF and ORBIT-AF programs.
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increased with increasing CHA2DS2-VASc score (Figure 3)
(because of very low numbers of ORBIT-AF I patients in
some categories, that cohort was excluded). Nearly half
of patients with CHA2DS2-VASc score of 0 and new-onset
AF received OAC (47% for GARFIELD-AF, 57% for
ORBIT-AF II). Among patients with CHA2DS2-VASc ≥2,
69% and 87% of patients in GARFIED-AF and ORBIT-AF II,
respectively, were treated with OAC. Among patients
with new AF and CHA2DS2-VASc score ≥2, there was
significant geographic variability in use of OAC across
countries, from 31% to 93% in GARFIELD-AF and, across
states within the United States, from 66% to 100% in
ORBIT-AF II (Figure 4). For such patients in GARFIELD-AF
enrolled from the United States, OAC use was 72%
compared with 84% for the comparable ORBIT-AF US
cohort.Discussion
These analyses represent a global assessment of AF
care, encompassing N70,000 patients from the
GARFIELD-AF and ORBIT-AF I and II cohorts. Despite
baseline differences in ethnic composition, overall
comorbidities and risk profiles among patients with AFglobally appear consistent across cohorts. Additionally,
there have been major shifts in therapies for prevention
of stroke in this population, including a move away from
antiplatelet monotherapy and toward oral anticoagulation
with NOACs around the world. However, the use of oral
anticoagulation is common in patients with a low stroke
risk (CHA2DS2-VASc score 0-1) but not consistently
implemented in patients with a high stroke risk (CHA2-
DS2-VASc ≥2). Regional differences in treatment (both
within the United States and between countries) may
account for some of the undertreatment in higher-risk
patients.
Our data add to those of several administrative claims
analyses demonstrating anticoagulation underutilization
for patients with AF.8,9 Although those studies capture
large numbers of patients, claims data are primarily
limited in the granularity of data available and usually
isolated to single-country data sets. The present
analyses also complement those of a worldwide
epidemiology study assessing the global health burden
and cost of AF.2 Those investigators demonstrated
increasing prevalence and associated disease morbidity
from AF from 1990 to 2010. However, specific
population characteristics were outside the scope of
that analysis. Our data provide details of the AF
Figure 3
aseline use of OAC in patients with new-onset AF by CHA2DS2-
ASc risk strata in GARFIELD-AF and ORBIT-AF II. Data from ORBIT-
F I were excluded because of very low numbers of patients in some
trata.
Figure 2
Antiplatelet and anticoagulation therapies in patients with new-onset AF within 6 weeks in (A) GARFIELD-AF and (B) ORBIT-AF. AP, antiplatelet;
VKA, vitamin K antagonist.
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the contributors to AF-associated health care expendi-
tures. Both in the United States and around the world,
patients with AF in our analysis were predominantly
elderly, with high rates of cardiovascular risk factors as
well as manifest cardiovascular disease.
We identified promising trends in oral anticoagulation
for AF. Major, randomized clinical trials have demon-
strated noninferiority or superiority of each NOAC
compared with warfarin for stroke prevention,10-13
and a meta-analysis of these trials demonstrated very
favorable risk-benefit profile for NOACs as a class.14
Based on these data, shifting from warfarin to NOACs at
the population level should decrease thromboembolic
and bleeding rates for patients with AF. Additional
analyses from these cohorts will examine whether such
improvements are realized in clinical practice. These
data also reflect a progressive shift away from antiplate-
let therapy for stroke prevention in AF, as it is
increasingly recognized to be of little benefit and not
insignificant risk.15-17
Our data demonstrated that for patients with new onset
AF, nearly half of patients at low-risk of stroke were
anticoagulated, yet only two-thirds of patients at high risk
of stroke received appropriate OAC therapy. There may
be several explanations for this paradox. The low-risk
patients with new-onset AF may be receiving OAC in the
setting of cardioversion, which could be appropriate for
patients of any CHA2DS2-VASc score. However,
risk-treatment paradoxes are well documented in local
cohorts of AF patients, where the lowest-risk patients
often receive aggressive therapy.18 Physicians may
perceive lower risk of causing harm in these patients,
although their potential benefit is also lower. Our dataB
V
A
sdemonstrate that this is not an isolated phenomenon.
Among patients with CHA2DS2-VASc score of 1, OAC use
rose to 55% in the GARFIELD-AF cohort and 65% in the
ORBIT-AF II group. The appropriate target treatment
rate is difficult to gauge, as there are few data to guide
therapy in this “intermediate”-risk group—therefore,
the latest US and European guidelines carry much
weaker recommendations for these patients.19,20 Nev-
ertheless, the overtreatment with anticoagulation of
patients at very low risk of stroke (CHA2DS2-VASc = 0)
would convey a significantly increased risk of bleeding
in these patients, with likely little benefit in terms of
thromboembolism prevention. In contrast, suboptimal
Figure 4
Baseline use of OAC in patients with new-onset AF and CHA2DS2-VASc ≥2 within 6 weeks by country (A) and by state or territory of the
United States (B) with at least 20 patients. Data in panel A are derived from GARFIELD-AF and ORBIT-AF; data in panel B are from ORBIT-
AF II alone.
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at the highest stroke risk (CHA2DS2-VASc ≥2) likely
risks potentially preventable thromboembolic events.
Our analysis of regional variability in OAC use
demonstrates significant heterogeneity and may ac-
count, in part, for the apparent undertreatment of
high-risk patients. Furthermore, variability in treatment
appears not only at the country level across the
GARFIELD-AF study but also more locally at the state
level in the ORBIT-AF program. This suggests that such
differences in treatment result from local practice
variation and not necessarily system-wide differences in
management among locales, and represents an opportu-
nity for education and improvement in quality of care for
patients. As the burden of disease continues to increase, it
remains imperative to appropriately implement treat-
ments, targeted to local care delivery models, to improve
outcomes and reduce health care costs worldwide.Limitations
There may be sampling and/or selection biases in these
observational, registry data. Additionally, there was a
geographic imbalance in enrollment of patients, and
some regions may be overrepresented, with the potential
for regional differences in diagnoses and treatments.
Lastly, differences in design and enrollment criteria must
be considered when comparing GARFIELD-AF, ORBIT-AF
I, and ORBIT-AF II. Data were acquired via medical record
review, and each study had its own data verification and
auditing protocol.Conclusions
Despite regional, ethnic, and other differences, patients
with AF worldwide demonstrate similar risk profiles and
manifest a significant burden of comorbid cardiovascular
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increasing worldwide, with a concomitant decrease in
the use of antiplatelet therapies. However, among
new-onset AF, oral anticoagulation is commonly used in
the lowest-risk patients, for unclear reasons. Further-
more, it is inconsistently prescribed to patients with a
high risk of stroke. The significant geographic variability
in the use of OAC represents an opportunity for education
and implementation of consistent guideline-based
recommendations.
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